Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab175856-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$49.90
|
|
|
Ab175856-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$207.90
|
|
|
Ab175856-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$537.90
|
|
|
Ab175856-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$837.90
|
|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Gevokizumab (anti-IL-1b) - Primary antibody, specific to IL1B, >95%, high purity, Human IgG2, NEGATIVE ALLOSTERIC MODULATOR of Interleukin-1 beta negative allosteric modulator |
|---|---|
| Synonyms | Catabolin antibody | H1 antibody | IFN beta inducing factor antibody | IL 1 antibody | IL 1 beta antibody | IL-1 beta antibody | IL1 antibody | IL1 BETA antibody | IL1B antibody | IL1B_HUMAN antibody | IL1F2 antibody | Interleukin 1 beta antibody | Interl |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | IL1B |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | NEGATIVE ALLOSTERIC MODULATOR |
| Mechanism of action | NEGATIVE ALLOSTERIC MODULATOR of Interleukin-1 beta negative allosteric modulator |
| Product Description |
Gevokizumab (anti-IL-1b) is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab (anti-IL-1b) selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II). |
| Isotype | Human IgG2 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 26.8 kDa (Light Chain) & 51.4 kDa (Heavy Chain), under reducing conditions; 170.1 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1129435-60-4 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Gevokizumab (anti-IL-1b) (Ab175856) - ELISA
Immobilized Recombinant Human IL-1 beta Protein (rp147346) at 1.0 μg/mL can bind Gevokizumab (anti-IL-1b) (Ab175856) with the EC₅₀ of 56.74 ng/mL.
Gevokizumab (anti-IL-1b) (Ab175856) - SEC
The purity of Gevokizumab (anti-IL-1b) (Ab175856) is more than 95% verified by HPLC.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Nov 02, 2023 | Ab175856 | |
| Certificate of Analysis | Nov 02, 2023 | Ab175856 |
Starting at $109.90
Starting at $119.90